First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

NCT06097455 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Refractory Non-Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma

Interventions

GENETIC: ARI0003

Sponsor

Fundacion Clinic per a la Recerca Biomédica